Cited by 884Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenetic factors in colorectal cancer

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Petitjean, A, Achatz, M I W, Borresen-Dale, A L, Hainaut, P, Olivier, M·2007·Oncogene

Open this paper in CoChat — free account

Abstract

A large amount of data is available on the functional impact of missense mutations in TP53 and on mutation patterns in many different cancers. New data on mutant p53 protein function, cancer phenotype and prognosis have recently been integrated in the International Agency for Research on Cancer TP53 database (http://www-p53.iarc.fr/). Based on these data, we summarize here current knowledge on the respective roles of mutagenesis and biological selection of mutations with specific functional characteristic in shaping the patterns and phenotypes of mutations observed in human cancers. The main conclusion is that intrinsic mutagenicity rates, loss of transactivation activities, and to a lesser extent, dominant-negative activities are the main driving forces that determine TP53 mutation patterns and influence tumor phenotype. In contrast, current experimental data on the acquisition of oncogenic activities (gain of function) by p53 mutants are too scarce and heterogenous to assess whether this property has an impact on tumor development and outcome. In the case of inherited TP53 mutations causing Li-Fraumeni and related syndromes, the age at onset of some tumor types is in direct relation with the degree of loss of transactivation capacity of missense mutations. Finally, studies on large case series demonstrate that TP53 mutations are independent markers of bad prognosis in breast and several other cancers, and that the exact type and position of the mutation influences disease outcome. Further studies are needed to determine how TP53 haplotypes or loss of alleles interact with mutations to modulate their impact on cancer development and prognosis.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210302

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Surfing the p53 network
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“191117) encodes a transcription factor which is activated in response to several forms of cellular stress and exerts multiple, antiproliferative functions (Vogelstein et al., 2000).”
Background
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Patterns of somatic mutation in human cancer genomes
Greenman, C. D., Stephens, P., Smith, R., Dalgliesh, G. L., Hunter, C., Bignell, G. R., Davies, H. R., Teague, J. W., Butler, A. P., Stevens, C., et al. (2007) · Nature · doi:10.1038/nature05610 · Cited by 3,143
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559

Show all 117 references

Research works printed but not linked: 1

Langerod A, Burdette L, Yeager M, Llaca V, Presswalla S, Gerhard DS et al. (2006a). Pattern of genetic variation in the tp53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. Hum Mutat (in press).

Sorted by citations

Items 101–200 of 883

Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas
Helbig, D., Ihle, M. A., Pütz, K., Tantcheva‐Poór, I., Mauch, C., Büttner, R., & Quaas, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7845 · Cited by 99
Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer
Lin, P., Kuo, W., Huang, A.-C., Lu, Y., Lin, C., Kuo, S., Wang, M.-Y., Liu, C., Cheng, F. T.-F., Yeh, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7027 · Cited by 97
Degradation of mutant p53H175 protein by Zn(II) through autophagy
Garufi, A., Pucci, D., D’Orazi, V., Cirone, M., Bossi, G., Avantaggiati, M. L., & D’Orazi, G. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.217 · Cited by 97
Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
Song, B., Yang, P., & Zhang, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12520 · Cited by 103
BK Virus as a Cofactor in the Etiology of Prostate Cancer in Its Early Stages
Das, D., Wojno, K. J., & Imperiale, M. J. (2007) · Journal of Virology · doi:10.1128/jvi.02461-07 · Cited by 95
Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation
Gurpinar, E., & Vousden, K. H. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.04.001 · Cited by 98
Oncometabolites drive tumorigenesis by enhancing protein acylation: from chromosomal remodelling to nonhistone modification
Fu, Y., Yu, J., Li, F., & Ge, S. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02338-w · Cited by 104
p53, a Target of Estrogen Receptor (ER) α, Modulates DNA Damage-induced Growth Suppression in ER-positive Breast Cancer Cells
Berger, C. E., Qian, Y., Liu, G., Chen, H.-W., & Chen, X. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.367326 · Cited by 93
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
Leroy, B., Ballinger, M. L., Baran‐Marszak, F., Bond, G. L., Braithwaite, A. W., Concin, N., Donehower, L. A., El‐Deiry, W. S., Fenaux, P., Gaïdano, G., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2179 · Cited by 95
Self-citation
Prognostic Significance of Truncating TP53 Mutations in Head and Neck Squamous Cell Carcinoma
der Plas, M. L.-V., Brakenhoff, R. H., Kuik, D. J., Buijze, M., Bloemena, E., Snijders, P. J. F., Leemans, C. R., & Braakhuis, B. J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0183 · Cited by 93
P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients
Pan, Y., Yuan, Y., Liu, G., & Wei, Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172324 · Cited by 94
Eyelid Sebaceous Carcinoma: Clinicopathologic and Multiparametric Immunohistochemical Analysis That Includes Adipophilin
Jakobiec, F. A., & Mendoza, P. R. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.08.015 · Cited by 90
Fine Mapping of Chromosome 6q23-25 Region in Familial Lung Cancer Families Reveals RGS17 as a Likely Candidate Gene
You, M., Wang, D., Liu, P., Vikis, H. G., James, M. A., Lü, Y., Wang, Y., Wang, M., Chen, Q., Jia, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2335 · Cited by 90
p53, a translational regulator: contribution to its tumour-suppressor activity
Marcel, V., Catez, F., & Diaz, J. (2015) · Oncogene · doi:10.1038/onc.2015.25 · Cited by 94
NFκB/p53 crosstalk—a promising new therapeutic target
Schneider, G., & Krämer, O. H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.10.003 · Cited by 87
The Natural History of Vulvar Intraepithelial Neoplasia, Differentiated Type: Evidence for Progression and Diagnostic Challenges
Bigby, S. M., Eva, L., Fong, K. L., & Jones, R. W. (2016) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000280 · Cited by 87
p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma
Doyle, B. J., Morton, J. P., Delaney, D., Ridgway, R. A., Wilkins, J. A., & Sansom, O. J. (2010) · The Journal of Pathology · doi:10.1002/path.2748 · Cited by 88
The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis
Yang, P., Du, C., Kwan, M., Liang, S.-X., & Zhang, G. J. (2013) · Scientific Reports · doi:10.1038/srep02246 · Cited by 94
Effects of TP53 mutational status on gene expression patterns across 10 human cancer types
Parikh, N., Hilsenbeck, S. G., Creighton, C. J., Dayaram, T., Shuck, R. L., Shinbrot, E., Liu, X., Gibbs, R. A., Wheeler, D. A., & Donehower, L. A. (2013) · The Journal of Pathology · doi:10.1002/path.4321 · Cited by 91
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
Towards an understanding of the role of p53 in adrenocortical carcinogenesis
Wasserman, J. D., Zambetti, G. P., & Malkin, D. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.010 · Cited by 84
Molecularly targeted therapies for p53-mutant cancers
Zhao, D., Tahaney, W. M., Mazumdar, A., Savage, M. I., & Brown, P. H. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2575-0 · Cited by 82
Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy
He, C., Li, L., Guan, X., Li, X., & Miao, X. (2016) · Chemotherapy · doi:10.1159/000446361 · Cited by 80
Exploring background mutational processes to decipher cancer genetic heterogeneity
Goncearenco, A., Rager, S. L., Li, M., Sang, Q. A., Rogozin, I. B., & Panchenko, A. R. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx367 · Cited by 76
Reviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 84
Somatic Mutaome Profile in Human Cancer Tissues
Kim, N., Hong, Y., Kwon, D., & Yoon, S. (2013) · Genomics & Informatics · doi:10.5808/gi.2013.11.4.239 · Cited by 79
TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li–Fraumeni syndrome: impact on age at first diagnosis
Marcel, V., Palmero, E. I., Falagan-Lotsch, P., Martel‐Planche, G., Ashton‐Prolla, P., Olivier, M., Brentani, H., Hainaut, P. L., & Achatz, M. I. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066704 · Cited by 78
Self-citation
Integrating gene regulatory pathways into differential network analysis of gene expression data
Grimes, T., Potter, S. S., & Datta, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41918-3 · Cited by 77
TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome
Ribi, S., Baumhoer, D., Lee, K., Edison, Teo, A. S. M., Madan, B., Zhang, K., Kohlmann, W. K., Yao, F., Lee, W. H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3115 · Cited by 75
TP53 Status and Response to Treatment in Breast Cancers
Varna, M., Bousquet, G., Plassa, L., Bertheau, P., & Janin, A. (2011) · BioMed Research International · doi:10.1155/2011/284584 · Cited by 87
p53 regulates the transcription of its Δ133p53 isoform through specific response elements contained within the TP53 P2 internal promoter
Marcel, V., Vijayakumar, V., Fernandez‐Cuesta, L., Hafsi, H., Sagne, C., Hautefeuille, A. H., Olivier, M., & Hainaut, P. L. (2010) · Oncogene · doi:10.1038/onc.2010.26 · Cited by 79
Self-citation
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer
Meric‐Bernstam, F., Zheng, X., Shariati, M., Damodaran, S., Wathoo, C., Brusco, L., Demirhan, M. E., Tapia, C., Eterovic, A. K., Basho, R. K., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00245 · Cited by 76
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
Bellutti, F., Tigan, A.-S., Nebenfuehr, S., Dolezal, M., Zojer, M., Grausenburger, R., Hartenberger, S., Kollmann, S., Doma, E., Prchal‐Murphy, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0912 · Cited by 75
Reactivation of mutant p53 by capsaicin, the major constituent of peppers
Garufi, A., Pistritto, G., Cirone, M., & D’Orazi, G. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0417-9 · Cited by 76
Watching the watcher: Regulation of p53 by mitochondria
Holley, A. K., & St Clair, D. K. (2009) · Future Oncology · doi:10.2217/14796694.5.1.117 · Cited by 75
30 years and a long way into p53 research
Hainaut, P. L., & Wiman, K. G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70198-6 · Cited by 80
Self-citation
Ovarian Cancer Update: Lessons From Morphology, Molecules, and Mice
Cho, K. R. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.11.1775 · Cited by 74
Mitochondrial Superoxide Dismutase - Signals of Distinction
Miriyala, S., Holley, A. K., & Clair, D. K. S. (2011) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152011795255920 · Cited by 74
Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53
Martinez-Rivera, M., & Siddik, Z. H. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.026 · Cited by 80
p53 isoforms - A conspiracy to kidnap p53 tumor suppressor activity?
Marcel, V., & Hainaut, P. L. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8336-3 · Cited by 79
Self-citation
Untold story of human cervical cancers: HPV-negative cervical cancer
Lee, J.-E., Chung, Y., Rhee, S., & Kim, T.-H. (2022) · BMB Reports · doi:10.5483/bmbrep.2022.55.9.042 · Cited by 78
P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case–control studies
Zhang, Z., Wang, M., Wu, D., Wang, M., Tian, Y., Tian, Y., & Zhang, Z. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0480-4 · Cited by 72
Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters
Lim, S. B., Lim, C. T., & Lim, W. (2019) · Cancers · doi:10.3390/cancers11101595 · Cited by 73
Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences
Brázdová, M., Quante, T., Tögel, L., Walter, K., Loscher, C., Tichý, V., Činčárová, L., Deppert, W., & Tolstonog, G. V. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn1085 · Cited by 72
Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: A systematic review
Tornesello, M. L., Buonaguro, L., & Buonaguro, F. M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.11.017 · Cited by 71
Explainable drug sensitivity prediction through cancer pathway enrichment
Tang, Y.-C., & Gottlieb, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-82612-7 · Cited by 74
Arg72Pro TP53 polymorphism and cancer susceptibility: A comprehensive meta‐analysis of 302 case‐control studies
Francisco, G., Menezes, P. R., Eluf‐Neto, J., & Chammas, R. J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25710 · Cited by 72
Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression
Yan, W., Zhang, Y., Jin, Z., Liu, S., Cho, S. J., & Chen, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.231639 · Cited by 71
Genotoxicity of tobacco smoke‐derived aromatic amines and bladder cancer: current state of knowledge and future research directions
Nia, A. B., & Tommasi, S. (2013) · The FASEB Journal · doi:10.1096/fj.12-227074 · Cited by 70
Targeting TYRO3 inhibits epithelial–mesenchymal transition and increases drug sensitivity in colon cancer
Chien, C.-W., Hou, P.-C., Wu, H.-C., Chang, Y.-L., Lin, S.-C., Lin, S.-C., Lin, B.-W., Lee, J.-C., Chang, Y.-J., Sun, H. S., et al. (2016) · Oncogene · doi:10.1038/onc.2016.120 · Cited by 71
Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model
Kucab, J. E., Phillips, D. H., & Arlt, V. M. (2010) · FEBS Journal · doi:10.1111/j.1742-464x.2010.07676.x · Cited by 70
The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes
Smith, M. J., Urquhart, J. E., Harkness, E. F., Miles, E. K., Bowers, N. L., Byers, H., Bulman, M. P., Gokhale, C., Wallace, A. J., Newman, W. G., et al. (2015) · Human Mutation · doi:10.1002/humu.22938 · Cited by 69
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
Stockhammer, P., Grant, M. J., Wurtz, A., Foggetti, G., Expósito, F., Gu, J., Zhao, H., Choi, J., Chung, S. T., Li, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.001 · Cited by 67
Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells
Zhao, J., Lü, Y., & Shen, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.09.040 · Cited by 72
TP53 drives invasion through expression of its Δ133p53β variant
Gadéa, G., Arsic, N., Fernandes, K., Diot, A., Joruiz, S. M., Abdallah, S., Meuray, V., Vinot, S., Anguille, C., Reményi, J., et al. (2016) · eLife · doi:10.7554/elife.14734 · Cited by 71
A genome‐wide si RNA screen for regulators of tumor suppressor p53 activity in human non‐small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment
Olst, E. S., Blijlevens, M., de Menezes, R. X., van der Meulen‐Muileman, I. H., Smit, E. F., & van Beusechem, V. W. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12052 · Cited by 65
Uncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer
Asada, K., Kobayashi, K., Joutard, S., Tubaki, M., Takahashi, S., Takasawa, K., Komatsu, M., Kaneko, S., Sese, J., & Hamamoto, R. (2020) · Biomolecules · doi:10.3390/biom10040524 · Cited by 67
A RNA sequencing-based six-gene signature for survival prediction in patients with glioblastoma
Zuo, S., Zhang, X., & Wang, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-39273-4 · Cited by 64
TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix
Tornesello, M. L., Annunziata, C., Buonaguro, L., Losito, S., Greggi, S., & Buonaguro, L. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0255-5 · Cited by 66
Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer
Lenos, K., Grawenda, A. M., Lodder, K., Kuijjer, M. L., Teunisse, A. F. A. S., Repapi, E., Grochola, L. F., Bartel, F., Hogendoorn, P. C. W., Wuerl, P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0215 · Cited by 65
Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen
Jeschke, J., Neste, L. V., Glöckner, S. C., Dhir, M., Calmon, M. F., Deregowski, V., Criekinge, W. V., Vlassenbroeck, I., Koch, A., Chan, T. A.-T., et al. (2012) · Epigenetics · doi:10.4161/epi.20445 · Cited by 65
Manganese superoxide dismutase vs. p53: Regulation of mitochondrial ROS
Holley, A. K., Dhar, S. K., & Clair, D. K. S. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.06.003 · Cited by 65
Activation of cAMP signaling inhibits DNA damage–induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation
Naderi, E. H., Findley, H. W., Ruud, E., Blomhoff, H. K., & Naderi, S. (2009) · Blood · doi:10.1182/blood-2009-02-204883 · Cited by 64
F-Box Proteins and Cancer
Yumimoto, K., Yamauchi, Y., & Nakayama, K. I. (2020) · Cancers · doi:10.3390/cancers12051249 · Cited by 65
More targets, more pathways and more clues for mutant p53
Garritano, S., Inga, A., Gemignani, F., & Landi, S. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.15 · Cited by 64
Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia
Ånensen, N., Hjelle, S. M., Belle, W. V., Haaland, I., Silden, E., Bourdon, J., Hovland, R., Taskén, K., Knappskog, S., Lønning, P. E., et al. (2011) · Oncogene · doi:10.1038/onc.2011.348 · Cited by 67
Integration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma
Chaddad, A., Daniel, P. M., Sabri, S., Desrosiers, C., & Abdulkarim, B. (2019) · Cancers · doi:10.3390/cancers11081148 · Cited by 61
Inactivation of p53 in Human Keratinocytes Leads to Squamous Differentiation and Shedding via Replication Stress and Mitotic Slippage
Freije, A., Molinuevo, R., Ceballos, L., Cagigas, M., Alonso‐Lecue, P., Rodrı́guez, R., Menéndez, P. R., Aberdam, D., de Diego, E., & Gandarillas, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.012 · Cited by 62
Cell cycle dependence on the mevalonate pathway: Role of cholesterol and non-sterol isoprenoids
Lasunción, M. A., Martínez-Botas, J., Martín-Sánchez, C., Busto, R., & Gómez‐Coronado, D. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114623 · Cited by 62
Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX
Coates, A. S., Millar, E. K. A., O'Toole, S. A., Molloy, T. J., Viale, G., Goldhirsch, A., Regan, M. M., Gelber, R. D., Sun, Z., Castiglione‐Gertsch, M., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3348 · Cited by 62
Myelodysplastic Syndromes Arising in Patients With Germline TP53 Mutation and Li-Fraumeni Syndrome
Talwalkar, S. S., Yin, C. C., Naeem, R. C., Hicks, J. M., Strong, L. C., & Abruzzo, L. V. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0015-oa.1 · Cited by 60
Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor
Scarr, E., Udawela, M., Thomas, E. A., & Dean, B. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.195 · Cited by 59
MALAT-1/p53/miR-155/miR-146a ceRNA circuit tuned by methoxylated quercitin glycoside alters immunogenic and oncogenic profiles of breast cancer
Abdel-Latif, M., Riad, A., Soliman, R. A., Elkhouly, A. M., Nafae, H., Gad, M. Z., Motaal, A. A. A., & Youness, R. A. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04378-4 · Cited by 59
Zinc Oxide Nanoparticles (ZnO-NPs) Suppress Fertility by Activating Autophagy, Apoptosis, and Oxidative Stress in the Developing Oocytes of Female Zebrafish
Mawed, S. A., Marini, C., Alagawany, M. M., Farag, M. R., Reda, R. M., El‐Saadony, M. T., Elhady, W. M., Magi, G. E., Cerbo, A. D., & El-Nagar, W. G. (2022) · Antioxidants · doi:10.3390/antiox11081567 · Cited by 59
Clinical utility of anti-p53auto-antibody: Systematic review and focus on colorectal cancer
Suppiah, A. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i29.4651 · Cited by 62
Genomics and the Immune Landscape of Osteosarcoma
Wu, C.-C., & Livingston, J. A. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-43085-6_2 · Cited by 58
Cross-Talk between p53 and Wnt Signaling in Cancer
Xiao, Q., Werner, J., Venkatachalam, N., Boonekamp, K. E., Ebert, M. P. A., & Zhan, T. (2022) · Biomolecules · doi:10.3390/biom12030453 · Cited by 59
AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10‐mediated regulatory pathway
Hrstka, R., Bouchalová, P., Michalová, E., Matoulková, E., Müller, P., Coates, P. J., & Vojtěšek, B. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.003 · Cited by 60
Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals
Lee, J.-G., Ahn, J., Kim, T. J., Lee, J. H., & Choi, J. (2015) · Scientific Reports · doi:10.1038/srep12642 · Cited by 60
Role of TP53 Mutations in Vulvar Carcinomas
Choschzick, M., Hantaredja, W., Tennstedt, P., Gieseking, F., Woelber, L. L., & Simon, R. (2011) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3182184c7a · Cited by 58
Myosin-X is essential to the intercellular spread of HIV-1 Nef through tunneling nanotubes
Uhl, J., Gujarathi, S., Waheed, A. A., Gordon, A., Freed, E. O., & Gousset, K. (2019) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-018-0493-z · Cited by 57
pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation
Boix, O., Martinez, M., Vidal, S., Giménez-Alejandre, M., Palenzuela, L., Lorenzo-Sanz, L., Quevedo, L., Moscoso, O., Ruiz‐Orera, J., Ximénez‐Embún, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34529-6 · Cited by 57
Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O6-methylguanine DNA-methyltransferase
Wang, X., Chen, J., Liu, Y., You, C., & Mao, Q. (2012) · Neurological Sciences · doi:10.1007/s10072-012-1257-9 · Cited by 57
Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy
Gill, H., Leung, A. Y. H., & Kwong, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040440 · Cited by 58
miR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma
Gu, Y., Liu, H., Kong, F., Ye, J., Jia, X., Zhang, Z., Li, N., Yin, J., Zheng, G., & He, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0834-z · Cited by 58
Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models
Moro, M., Paolo, D. D., Milione, M., Centonze, G., Bornaghi, V., Borzi, C., Gandellini, P., Perri, P., Pastorino, U., Ponzoni, M., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.07.006 · Cited by 57
Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells
Yoshikawa, K., Hamada, J., Tada, M., Kameyama, T., Nakagawa, K., Suzuki, Y., Ikawa, M., Hassan, N. M. M., Kitagawa, Y., & Moriuchi, T. (2010) · Biomedical Research · doi:10.2220/biomedres.31.401 · Cited by 55
WIP1 phosphatase as pharmacological target in cancer therapy
Pecháčková, S., Burdová, K., & Macůrek, L. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1536-2 · Cited by 57
Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes
Olivier, M., & Tanière, P. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283412dfa · Cited by 56
Self-citation
Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic
Vymetalkova, V. P., Pardini, B., Naccarati, A., Landi, S., Slyšková, J., Novotný, J. P., Vodičková, L., Bermejo, J. L., Hanova, M., Šmerhovský, Z., et al. (2009) · Human Mutation · doi:10.1002/humu.20931 · Cited by 56
Genome‐wide high‐resolution analysis of DNA copy number alterations in NF1‐associated malignant peripheral nerve sheath tumors using 32K BAC array
Mantripragada, K. K., de Ståhl, T. D., Patridge, C., Menzel, U., Andersson, R., Chuzhanova, N. A., Kluwe, L., Guha, A., Mautner, V., Dumanski, J. P., et al. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20695 · Cited by 55
Cyclophosphamide Dose Intensification May Circumvent Anthracycline Resistance of p53 Mutant Breast Cancers
Lehmann‐Che, J., André, F., Desmedt, C., Mazouni, C., Giacchetti, S., Turpin, E., Espié, M., Plassa, L., Marty, M. E., Bertheau, P., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0243 · Cited by 56
Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data
Liu, R., Rizzo, S., Waliany, S., Garmhausen, M. R., Pal, N., Huang, Z., Chaudhary, N., Wang, L. E., Harbron, C. G., Neal, J. W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01873-5 · Cited by 55
p53 in head and neck cancer: Functional consequences and environmental implications of TP53mutations
Peltonen, J. K., Helppi, H. M., Pääkkö, P. K., Turpeenniemi-Hujanen, T. M., & Vähäkangas, K. (2010) · Head & Neck Oncology · doi:10.1186/1758-3284-2-36 · Cited by 55
Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers
Ichimura, K., Narita, Y., & Hawkins, C. E. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1439-7 · Cited by 56
Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series
Montemurro, N., Fanelli, G. N., Scatena, C., Ortenzi, V., Pasqualetti, F., Mazzanti, C. M., Morganti, R., Paiar, F., Naccarato, A. G., & Perrini, P. (2021) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2021.106735 · Cited by 52
p53 isoform profiling in glioblastoma and injured brain
Takahashi, R., Giannini, C., Sarkaria, J. N., Schroeder, M., Rogers, J., Mastroeni, D., & Scrable, H. J. (2012) · Oncogene · doi:10.1038/onc.2012.322 · Cited by 52
TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer (Review)
Huszno, J., & Grzybowska, E. A. (2018) · Oncology Letters · doi:10.3892/ol.2018.8627 · Cited by 52
ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early stage gallbladder cancer
Iyer, P. S., Shrikhande, S. V., Ranjan, M., Joshi, A., Gardi, N., Prasad, R., Dharavath, B., Thorat, R. A., Salunkhe, S. J., Sahoo, B., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31916 · Cited by 52
MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population
Lum, S. S., Chua, H. W., Li, H., Li, W., Rao, N., Wei, J., Shao, Z., & Sabapathy, K. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn024 · Cited by 52

Authors: Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M.
Affiliations: Centre international de recherche sur le cancer (FR)
Corresponding author: Hainaut, P
ORCID: Petitjean, A
Achatz, M I W
Hainaut, P
Olivier, M
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2007-04-02
Volume: 26
Issue: 15
Pages: 2157-2165
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1210302
OpenAlex: W2042484101
Cited by: 884
References: 117
Citations by year: 2026: 16 · 2025: 29 · 2024: 29 · 2023: 50 · 2022: 55 · 2021: 52 · 2020: 50 · 2019: 53 · 2018: 60 · 2017: 46 · 2016: 57 · 2015: 52 · 2014: 53 · 2013: 43 · 2012: 48
FWCI: 5.08
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: TP53 mutation, missense mutations, dominant-negative p53, gain-of-function, mutagenesis, tumor phenotype, cancer prognosis, Li-Fraumeni syndrome, loss of heterozygosity, breast cancer
MeSH terms: Genetic Markers, Humans, Mutation, Neoplasms, Polymorphism, Genetic, Prognosis, Biomarkers, Tumor, Tumor Suppressor Protein p53, Mutagenesis, Li-Fraumeni Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks